Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Colorcon
McKesson
Moodys
Merck

Last Updated: December 6, 2022

Details for New Drug Application (NDA): 202971


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


NDA 202971 describes ABILIFY MAINTENA KIT, which is a drug marketed by Otsuka Pharm Co Ltd and is included in one NDA. It is available from one supplier. There are fourteen patents protecting this drug. Additional details are available on the ABILIFY MAINTENA KIT profile page.

The generic ingredient in ABILIFY MAINTENA KIT is aripiprazole. There are forty-nine drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the aripiprazole profile page.
Summary for 202971
Tradename:ABILIFY MAINTENA KIT
Applicant:Otsuka Pharm Co Ltd
Ingredient:aripiprazole
Patents:14
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 202971
Suppliers and Packaging for NDA: 202971
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ABILIFY MAINTENA KIT aripiprazole FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 202971 NDA Otsuka America Pharmaceutical, Inc. 59148-018 59148-018-71 1 KIT in 1 CARTON (59148-018-71) * 1.5 mL in 1 VIAL, SINGLE-USE * 5 mL in 1 VIAL, SINGLE-USE
ABILIFY MAINTENA KIT aripiprazole FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 202971 NDA Otsuka America Pharmaceutical, Inc. 59148-019 59148-019-71 1 KIT in 1 CARTON (59148-019-71) * 1.9 mL in 1 VIAL, SINGLE-USE * 5 mL in 1 VIAL, SINGLE-USE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULARStrength300MG/VIAL
Approval Date:Feb 28, 2013TE:RLD:Yes
Patent:See Plans and PricingPatent Expiration:Mar 8, 2034Product Flag?Substance Flag?Delist Request?
Patented Use:MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR 1 DISORDER
Patent:See Plans and PricingPatent Expiration:Mar 8, 2034Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF SCHIZOPHRENIA
Patent:See Plans and PricingPatent Expiration:Mar 8, 2034Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA

Expired US Patents for NDA 202971

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Otsuka Pharm Co Ltd ABILIFY MAINTENA KIT aripiprazole FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 202971-004 Sep 29, 2014 See Plans and Pricing See Plans and Pricing
Otsuka Pharm Co Ltd ABILIFY MAINTENA KIT aripiprazole FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 202971-004 Sep 29, 2014 See Plans and Pricing See Plans and Pricing
Otsuka Pharm Co Ltd ABILIFY MAINTENA KIT aripiprazole FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 202971-001 Feb 28, 2013 See Plans and Pricing See Plans and Pricing
Otsuka Pharm Co Ltd ABILIFY MAINTENA KIT aripiprazole FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 202971-003 Sep 29, 2014 See Plans and Pricing See Plans and Pricing
Otsuka Pharm Co Ltd ABILIFY MAINTENA KIT aripiprazole FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 202971-003 Sep 29, 2014 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Boehringer Ingelheim
Colorcon
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.